About Contact Us Careers
Sign In

Advanced Therapy Medicinal Products Market - Top Companies and Manufacturers

  • Report ID: 4684
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT
  1. Introduction
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Distributors
      3. End Users
    3. Secondary Research
    4. Market Size Estimation
  4. Executive Summary – Global Advanced Therapy Medicinal Products Market
  5. Analysis of Market Dynamics
    1. Drivers
    2. Trends
  6. Key Market Opportunities for Business Growth
  7. Major Roadblocks for the Market Growth
  8. Regulatory & Standard Landscape
  9. Value Chain Analysis
  10. Potential ATMP Treatment Analysis
  11. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
  12. Use Case Analysis
  13. Pipeline Analysis
  14. Analysis on the Manufacturing Process
  15. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
  16. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
  17. Competitive Positioning
  18. Competitive Landscape
    1. Market Share Analysis of Major Players (%), 2021
    2. Competitive Benchmarking
      1. Novartis AG.
      2. Takeda Pharmaceutical Company Limited
      3. Gilead Sciences, Inc.
      4. Bluebird Bio, Inc
      5. BioMarin Pharmaceutical Inc
      6. Vericel Corporation
      7. Mallinckrodt Pharmaceuticals
      8. UniQure N.V.
      9. JCR Pharmaceuticals Co., Ltd.
      10. Spark Therapeutics, Inc. (Parent Company: Roche)
      11. Kolon TissueGene, Inc. 
  19. Global Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2036F (USD million)
      2. Gene Therapy, 2023-2036F (USD million)
      3. Cell Therapy, 2023-2036F (USD million)
      4. Tissue Engineered Product, 2023-2036F (USD million)
    3. By Disease
      1. Oncology, 2023-2036F (USD million)
      2. Genetic Disorders, 2023-2036F (USD million)
      3. CNS, 2023-2036F (USD million)
      4. Dermatology, 2023-2036F (USD million)
      5. Others, 2023-2036F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2036F (USD million)
      2. Research & Academic Institutes, 2023-2036F (USD million)
    5. Global Advanced Therapy Medicinal Products Market by Region
      1. North America, 2023-2036F (USD million)
      2. Europe, 2023-2036F (USD million)
      3. Asia-Pacific, 2023-2036F (USD million)
      4. Latin America, 2023-2036F (USD million)
      5. Middle East & Africa, 2023-2036F (USD million)
  20. North America Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2036F (USD million
      2. Gene Therapy, 2023-2036F (USD million)
      3. Cell Therapy, 2023-2036F (USD million)
      4. Tissue Engineered Product, 2023-2036F (USD million)
    3. By Disease
      1. Oncology, 2023-2036F (USD million)
      2. Genetic Disorders, 2023-2036F (USD million)
      3. CNS, 2023-2036F (USD million)
      4. Dermatology, 2023-2036F (USD million)
      5. Others, 2023-2036F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2036F (USD million)
      2. Research & Academic Institutes, 2023-2036F (USD million)
    5. By Country
      1. US, 2023-2036F (USD million)
      2. Canada, 2023-2036F (USD million)
  21. Europe Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. UK, 2023-2036F (USD Million)
      2. Germany, 2023-2036F (USD Million)
      3. France, 2023-2036F (USD Million)
      4. Italy, 2023-2036F (USD Million)
      5. Spain, 2023-2036F (USD Million)
      6. Russia, 2023-2036F (USD Million)
      7. Netherlands, 2023-2036F (USD Million)
      8. Rest of Europe, 2023-2036F (USD Million)
  22. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. China, 2023-2036F (USD Million)
      2. India, 2023-2036F (USD Million)
      3. Japan, 2023-2036F (USD Million)
      4. South Korea, 2023-2036F (USD Million)
      5. Singapore, 2023-2036F (USD Million)
      6. Australia, 2023-2036F (USD Million)
      7. Rest of Asia-Pacific, 2023-2036F (USD Million)
  23. Latin America Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. Brazil, 2023-2036F (USD Million)
      2. Argentina, 2023-2036F (USD Million)
      3. Mexico, 2023-2036F (USD Million)
      4. Rest of Latin America, 2023-2036F (USD Million)
  24. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. GCC, 2023-2036F (USD Million)
      2. Israel, 2023-2036F (USD Million)
      3. South Africa, 2023-2036F (USD Million)
      4. Rest of Middle East & Africa, 2023-2036F (USD Million)

 

Companies Dominating the Advanced Therapy Medicinal Products Landscape

    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Bluebird Bio, Inc.
    • BioMarin Pharmaceuticals Inc.
    • Vericel Corporation
    • Mallinckrodt Pharmaceuticals
    • UniQure N.V.
    • JCR Pharmaceuticals Co., Ltd.
    • Spark Therapeutics, Inc.
    • Kolon TissueGene,Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • Novartis AG in collaboration with Medicines for Malaria Venture announced the entry of novel ganaplacide/lumenfantrine-SDF into the phase 3 study. This novel is a combination to treat uncomplicated malaria in both adults and children.

  • Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Zedira and Dr.Falk Pharma for the development of first in class Celiac disease therapy. It is a serious autoimmune disease, in which intake of gluten damages the small intestine.


Author Credits:  Radhika Pawar


  • Report ID: 4684
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of advanced therapy medicinal products is estimated at USD 14.63 billion.

The advanced therapy medicinal products market size was over USD 13.21 billion in 2024 and is projected to cross USD 67.8 billion by the end of 2037, witnessing more than 13.3% CAGR during the forecast period i.e., between 2025-2037. Rising instances of gene mutation and neurological condition, increased investment in the research and development of advance therapy medicinal products and higher demand of gene therapy will impel the market growth.

North America is poised to hold largest industry share of 44% by 2037, attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products.

The major players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample